Trends in Hepatocellular Carcinoma among Hepatitis C Patients Achieving Sustained Virological Response Following Direct-Acting Antivirals Treatment
DOI:
https://doi.org/10.24871/25320241-2Abstract
-References
Fiehn F, Beisel C, Binder M. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals. Curr Opin Virol. 2024;67:101423. doi:10.1016/j.coviro.2024.101423
World Health Organization. Global Hepatitis Report 2024 Action for Access in Low- and Middle-Income Countries. World Health Organization; 2024.
Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118-126. doi:10.1016/j.pharmthera.2017.10.009
Hashim A, Almahdi F, Albaba EA, et al. Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia. J Epidemiol Glob Health. 2020;10(2):178. doi:10.2991/jegh.k.200117.002
Ahn YH, Lee H, Kim DY, et al. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C. Gut Liver. 2021;15(3):410-419. doi:10.5009/gnl20151
Alarfaj SJ, Alzahrani A, Alotaibi A, et al. The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharm J. 2022;30(10):1448-1453. doi:10.1016/j.jsps.2022.07.005
Ali H, Vikash F, Moond V, et al. Global trends in hepatitis C-related hepatocellular carcinoma mortality: A public database analysis (1999-2019). World J Virol. 2024;13(1). doi:10.5501/wjv.v13.i1.89469
Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol. 2020;26(43):6770-6781. doi:10.3748/wjg.v26.i43.6770
Chan PPY, Levy MT, Shackel N, Davison SA, Prakoso E. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Hepatobiliary Pancreat Dis Int. 2020;19(6):541-546. doi:10.1016/j.hbpd.2020.06.013
Rinaldi L, Nevola R, Franci G, et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers (Basel). 2020;12(6):1351. doi:10.3390/cancers12061351
El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64(1):130-137. doi:10.1002/hep.28535
Lv GJ, Ji D, Yu L, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Hepatol Int. 2024;18(5):1459-1471. doi:10.1007/s12072-024-10700-7
Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol. 2022;28(1):96-107. doi:10.3748/wjg.v28.i1.96
The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.; 2023. www.hcvguidelines.org
Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther. 2022;22(6):621-632. doi:10.1080/14737140.2022.2074404
Shiha G, Mousa N, Soliman R, NNH Mikhail N, Adel Elbasiony M, Khattab M. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study. J Viral Hepat. 2020;27(7):671-679. doi:10.1111/jvh.13276
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).